Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1Recurrence 1Paraproteinemias 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoproliferative Disorders 1Hematologic Diseases 1Blood Protein Disorders 1

Interventions

fludarabine phosphate 4fludarabine 4Cyclophosphamide 4blinatumomab 3ponatinib 2ibrutinib 2Whole-Body Irradiation 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mycophenolic Acid 2Mesna 2Melphalan 2Busulfan 2Bone Marrow Transplantation 2AP 1903 reagent 2pegaspargase 1durvalumab 1asparaginase erwinia chrysanthemi recombinant 1Rituximab 1Pharmacogenomic Testing 1Methotrexate 1Lenalidomide 1KW-2478 1Imatinib Mesylate 1Ifosfamide 1Hsp90 inhibitor KU757 1Dexamethasone 1Daunorubicin 1CLR1404 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Immunoproliferative Disorders × CLR1404 × Other hematologic neoplasm × Clear all
NCT02952508 2026-03-18

CLOVER-WaM

Cellectar Biosciences, Inc.

Phase 2 Active not recruiting
120 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Blood Protein Disorders, Hematologic Diseases, Immunoproliferative Disorders, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Paraproteinemias, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡